Endeavor Sprint Drug-Eluting Stent Offered on Rapid Exchange System


November 13, 2008

The Endeavor Sprint drug-eluting stent (DES) is now offered on a rapid exchange (RX) delivery system.
Using the Sprinter balloon catheter technology, the Endeavor Sprint system puts the Endeavor DES on an enhanced delivery platform, making Medtronic’s flagship DES easier for physicians to deliver to the site of coronary blockages. The Endeavor Sprint system incorporates a new tip design for a low profile, a new balloon material and an enhanced shaft design which together greatly improve the device’s deliverability.

The ENDEAVOR clinical program has demonstrated the Endeavor stent is associated with low rates of stent thrombosis, myocardial infarction and cardiac death, as well as low and comparable rates of clinically-driven target lesion revascularization, out to as long as five years of patient follow-up. Representing various world geographies and patient subsets, the program has enrolled more than 10,000 subjects to date and will ultimately enroll more than 20,000 subjects in a combination of randomized controlled and single-arm clinical trials.

For more information: www.medtronic.com